CD79A and neoplasm: We found that, in the low-expression subgroup, the DEGs were significantly involved in multiple tumor- and immune-related pathways, such as leukocyte trans-endothelial migration, cytokine–cytokine receptor interaction, intestinal immune network for IgA production, graft-versus-host disease, primary immunodeficiency, autoimmune thyroid disease, glycosaminoglycan degradation, lysosome, ECM–receptor interaction, and glutathione metabolism (Figures 5C, D).